Cite
HARVARD Citation
Lawrence, S. et al. (2022). Optimized Infliximab Induction Predicts Better Long-Term Clinical and Biomarker Outcomes Compared to Standard Induction Dosing. Journal of pediatric gastroenterology and nutrition. 75 (5), pp. 601-607. [Online].